ProBIOPSY:前列腺穿刺活检标准的多学科国际共识
针对前列腺活检缺乏标准化的问题,该项目通过系统综述与三轮改良Delphi流程(34名国际专家)形成共识。36个条目中29个达成共识(81%),支持在影像质量充分时采用双参数或多参数MRI,并统一了靶向联合病灶周围活检方案的关键要素。共识认为靶向活检策略可满足多数临床场景,但特定适应症仍需额外对侧采样。
要点
- 影像质量充分时,双参数与多参数MRI均可纳入诊断路径。
- 靶向联合病灶周围活检方案的关键要素已达成共识。
- 靶向±病灶周围活检可满足多数局部治疗规划,但局灶治疗筛选等特定指征仍需对侧采样。
核心结论
- ProBIOPSY共识为前列腺活检提供了当代标准化框架。
- 靶向活检策略可满足多数临床场景,但无单一方案能为所有治疗决策提供完整信息,需按指征定制活检。
研究设计与样本
- 系统综述为条目制定提供依据,随后开展三轮改良Delphi流程,涉及34名国际专家。
- 专家在第1至3轮分别评估96、99和112条陈述,归为36个条目,共识采用改良RAND适宜性方法评估。
主要发现
- 全部专家完成三轮评估,36个条目中29个达成共识(81%)。
- 双参数和多参数MRI在影像质量充分时均被认可纳入诊断路径。
- 靶向联合病灶周围活检方案的关键要素得到统一。
- 靶向±病灶周围活检被认为足以满足多数局部治疗规划方面,但特定指征仍需额外对侧采样。
关键数值与推荐
- 36个条目中29个达成共识(81%)。
- 双参数和多参数MRI被认可纳入诊断路径的条件是影像质量充分。
- 靶向±病灶周围活检对多数局部治疗规划方面被视为充分。
- 对侧采样在特定指征(尤其是局灶治疗候选筛选)中仍显必要。
临床怎么用
- 在影像质量充分的前提下,可将双参数或多参数MRI纳入前列腺活检诊断路径。
- 采用靶向联合病灶周围活检方案时参考共识统一的关键要素。
- 多数局部治疗规划可基于靶向±病灶周围活检,但局灶治疗筛选等特定指征应附加对侧采样。
局限性
- 专家组成存在专业代表性不均衡。
- 各主题的专业知识存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate biopsy is a complex, multi-step procedure lacking standardisation across patient selection, tools, technique, and biopsy strategy, potentially influencing local treatment planning. An international consensus project was initiated to harmonise these aspects. METHODS AND ANALYSIS: A systematic review informed statement development. A modified Delphi process involving 34 international experts was conducted over three rounds. Panellists evaluated 96, 99, and 112 statements in Rounds 1-3, respectively, grouped into 36 stems. Statements were iteratively revised based on feedback and discussion. Consensus was assessed using a modified RAND appropriateness method. KEY FINDINGS AND LIMITATIONS: All experts completed the three rounds. Consensus was achieved for 29 of 36 stems (81%). Both biparametric and multiparametric magnetic resonance imaging were endorsed within the diagnostic pathway, provided imaging quality is adequate. Key elements of a targeted plus perilesional biopsy scheme were harmonised. For treatment planning, a targeted ± perilesional biopsy scheme was considered sufficient for most aspects of local treatment planning. However, additional contralateral sampling still seems necessary for specific indications, notably focal therapy candidate selection. Limitations include imbalances in specialty representation and heterogeneity in expertise across topics. CONCLUSION AND CLINICAL IMPLICATIONS: The ProBIOPSY consensus defines a contemporary, standardised framework for prostate biopsy. While targeted-based strategies are sufficient for most clinical scenarios, no single biopsy approach provides complete information for all treatment decisions, underscoring the need for indication-specific biopsy tailoring.
引用
- Chernysheva D, Di Bello F, Avesani G, et al. ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy. Eur Urol. 2026. PMID: 42420069. doi:10.1016/j.eururo.2026.06.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。